MRI
Magnetic-field imaging that is especially useful for soft tissue, brain, and spine assessment.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Purpose of the test
- Assess for brain or spinal cord involvement.
- Assess soft tissue in detail.
Informs decisions
- Planning radiotherapy or surgery.
- Assessment of neurological symptoms.
How the test is done
The patient lies inside a device with a magnetic field; inspection takes longer.
- Sample type
- Not invasive
- Estimated result time
- Results can be read on the same or next day.
Limitations
- A longer inspection time is required.
- Special adjustments are needed if the patient uses certain implants.
Related
Cancer types
Not displayed
TanyaKanker does not display test-cost estimates. Ask the laboratory or facility providing the test for cost details directly.
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
To check
- Liver Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Colorectal Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Oncology intervention (interventional radiology)
Treatment category
Reason: Memerlukan pemeriksaan
- Proton therapy
Treatment category
Reason: Memerlukan pemeriksaan
- Brain Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Pancreatic Cancer
Cancer type
Reason: Memerlukan pemeriksaan
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.